BIOMAT Database Logo BIOMAT Database Logo

Effect of an aldose reductase inhibitor on abnormalities of electroretinogram and vascular factors in diabetic rats. 1997

N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and T Hara, and Y Hamada, and H Fukasawa, and H Kakuta, and N Sakamoto
The Third Department of Internal Medicine, Nagoya University School of Medicine, Showa-ku, Japan.

The effect of an aldose reductase inhibitor, [5-(3-thienyl) tetrazol-1-yl] acetic acid (TAT), on the electroretinogram was determined in rats with streptozotocin-induced diabetes. Laboratory chow containing 0.05% TAT was given to rats for 2 months, while other diabetic rats were untreated. Groups of TAT-treated and untreated normal rats were also studied. Treatment with TAT produced significant improvement of the electroretinogram. TAT shortened the peak latencies of the b-wave oscillatory potentials, which were significantly prolonged in untreated diabetic rats (P < 0.0001 vs. untreated normal rats). This was accompanied by a significant decrease in the retinal sorbitol and fructose concentrations (by 46.5% and 25.7%, respectively). TAT treatment of diabetic rats also markedly reduced ADP-induced platelet aggregation and significantly increased the red blood cell 2,3-diphosphoglycerate level, accompanied by a marked reduction in sorbitol and fructose concentrations of platelet and red blood cells. There were significant correlations between the summed b-wave peak latencies and platelet aggregation or the 2,3-diphosphoglycerate level in diabetic rats. These findings suggest that an aldose reductase inhibitor, TAT, has therapeutic value for diabetic retinopathy.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008297 Male Males
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D012160 Retina The ten-layered nervous tissue membrane of the eye. It is continuous with the OPTIC NERVE and receives images of external objects and transmits visual impulses to the brain. Its outer surface is in contact with the CHOROID and the inner surface with the VITREOUS BODY. The outer-most layer is pigmented, whereas the inner nine layers are transparent. Ora Serrata
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D003925 Diabetic Angiopathies VASCULAR DISEASES that are associated with DIABETES MELLITUS. Diabetic Vascular Complications,Diabetic Vascular Diseases,Microangiopathy, Diabetic,Angiopathies, Diabetic,Angiopathy, Diabetic,Diabetic Angiopathy,Diabetic Microangiopathies,Diabetic Microangiopathy,Diabetic Vascular Complication,Diabetic Vascular Disease,Microangiopathies, Diabetic,Vascular Complication, Diabetic,Vascular Complications, Diabetic,Vascular Disease, Diabetic,Vascular Diseases, Diabetic
D003930 Diabetic Retinopathy Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION. Diabetic Retinopathies,Retinopathies, Diabetic,Retinopathy, Diabetic
D004163 Diphosphoglyceric Acids Glyceric acids where two of the hydroxyl groups have been replaced by phosphates. Bisphosphoglycerates,Acids, Diphosphoglyceric

Related Publications

N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and T Hara, and Y Hamada, and H Fukasawa, and H Kakuta, and N Sakamoto
The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats.
October 1994, Diabetes research and clinical practice,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and T Hara, and Y Hamada, and H Fukasawa, and H Kakuta, and N Sakamoto
Effects of an aldose reductase inhibitor on gastroenteropathy in streptozotocin-diabetic rats.
November 2003, Diabetes research and clinical practice,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and T Hara, and Y Hamada, and H Fukasawa, and H Kakuta, and N Sakamoto
Aldose reductase inhibition and glomerular abnormalities in diabetic rats.
August 1989, Diabetes,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and T Hara, and Y Hamada, and H Fukasawa, and H Kakuta, and N Sakamoto
Effect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patients.
January 2005, Hepato-gastroenterology,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and T Hara, and Y Hamada, and H Fukasawa, and H Kakuta, and N Sakamoto
Effect of an aldose reductase inhibitor on alveolar bone loss associated with periodontitis in diabetic rats.
May 2010, Postgraduate medicine,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and T Hara, and Y Hamada, and H Fukasawa, and H Kakuta, and N Sakamoto
Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor.
November 1989, Investigative ophthalmology & visual science,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and T Hara, and Y Hamada, and H Fukasawa, and H Kakuta, and N Sakamoto
Effect of an aldose reductase inhibitor on diabetic peripheral neuropathy. Preliminary report.
February 1981, Archives of neurology,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and T Hara, and Y Hamada, and H Fukasawa, and H Kakuta, and N Sakamoto
Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats.
January 2014, Journal of diabetes research,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and T Hara, and Y Hamada, and H Fukasawa, and H Kakuta, and N Sakamoto
Treatment with aldose reductase inhibitor or with myo-inositol arrests deterioration of the electroretinogram of diabetic rats.
August 1985, The Journal of clinical investigation,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and T Hara, and Y Hamada, and H Fukasawa, and H Kakuta, and N Sakamoto
Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats.
November 1995, Diabetes research and clinical practice,
Copied contents to your clipboard!